Nektar Therapeutics (NKTR)

20.22
0.12 0.60
NASDAQ : Health Technology
Prev Close 20.10
Open 20.13
Day Low/High 19.81 / 20.40
52 Wk Low/High 16.56 / 62.70
Volume 1.76M
Avg Volume 2.62M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 3.63B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Novo Nordisk Sales Climb

Novo Nordisk Sales Climb

The company expects to resume testing an inhaled insulin device during the first quarter.

Insulin Firms Waiting to Inhale

Insulin Firms Waiting to Inhale

The FDA's decision on Exubera could have far-reaching effects.

Nektar Changes Finance Chiefs

Lou Drapeau replaces Ajay Bansal.

Lipitor Still Key to Pfizer's Future

The company's earnings Thursday may take a back seat to an update on the cholesterol drug.

Pfizer, Sanofi End Exubera Pact

Pfizer will pay $1.3 billion to buy out Sanofi-Aventis' share of Exubera.

Exubera Getting More Review

The FDA tells Pfizer it will need three more months to review the inhaled insulin application.

Exubera Gets Good Marks

Exubera Gets Good Marks

A regulatory committee recommends approval of the inhalable insulin.

Health Stocks in Motion

Health Stocks in Motion

Gene Logic falls on impairment.

Health Stocks in Motion

Health Stocks in Motion

Dentsply gains.

Cramer's 'Mad Money Lightning Round': Best Buy Still True to Its Name

Cramer's 'Mad Money Lightning Round': Best Buy Still True to Its Name

Cramer says that the retailer is still best of breed despite a profit warning.

Health Stocks in Motion

Health Stocks in Motion

Biovail runs on painkiller approval.

FDA Panel Backs Inhaled Insulin

FDA Panel Backs Inhaled Insulin

The advisory committee votes 7-2 to support Exubera.

Options in Motion: McDonald's

Bullish call buying picks up following an upgrade.

Lilly Makes Bid for Respect

Lilly Makes Bid for Respect

Investors will key on diabetes and neuroscience franchises when the company reports Thursday.

MannKind's Work Is Never Done

Alfred E. Mann's company has a fierce fight in the inhaled insulin market.

Exubera Found Effective in Trials

Exubera Found Effective in Trials

Pfizer says an analysis of two clinical trials involved 304 adults with diabetes.

Exubera-nce in the Insulin Market

Exubera-nce in the Insulin Market

Competitors may gain from a quick approval for Exubera, an inhaled insulin product.

High Stakes for Inhaled Insulin

High Stakes for Inhaled Insulin

Players in the crowded arena await an FDA decision later this year.

Still Watching for a Washout Low

More extremely oversold Arms Index moving averages and big downside action in the markets would end the decline.

Pfizer Loses Some Luster

Pfizer Loses Some Luster

The drug giant's stock hits a one-year low, and more disappointment lurks around the bend.

Health Stocks in Motion

Health Stocks in Motion

Nektar Therapuetics rises on inhaled insulin study.

Weekend Reading: Jobs Data Surprise Becomes Fed Fear

The household survey offers some comfort but the FOMC's Tuesday meeting still will be the coming week's major economic event.

The Quest for Volatility Continues

Biotech is usually a good place to look, as Nektar Therapeutics showed today.

Health Stocks in Motion

Health Stocks in Motion

Kos Pharmaceuticals rises on big earnings beat.

Net Stocks Fly Right

So far this group's having an extraordinary year, even when skeptics predict their demise.

TheStreet Quant Rating: D (Sell)